tiprankstipranks
Trending News
More News >
GT Biopharma (GTBP)
NASDAQ:GTBP
Advertisement

GT Biopharma (GTBP) Price & Analysis

Compare
245 Followers

GTBP Stock Chart & Stats


GT Biopharma News

GTBP FAQ

What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.96 and its highest was $4.10 in the past 12 months.
    What is GT Biopharma’s market cap?
    GT Biopharma’s market cap is $4.73M.
      When is GT Biopharma’s upcoming earnings report date?
      GT Biopharma’s upcoming earnings report date is Nov 04, 2025 which is in 72 days.
        How were GT Biopharma’s earnings last quarter?
        GT Biopharma released its earnings results on Aug 06, 2025. The company reported -$0.548 earnings per share for the quarter, beating the consensus estimate of -$0.55 by $0.002.
          Is GT Biopharma overvalued?
          According to Wall Street analysts GT Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does GT Biopharma pay dividends?
            GT Biopharma does not currently pay dividends.
            What is GT Biopharma’s EPS estimate?
            GT Biopharma’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does GT Biopharma have?
            GT Biopharma has 3,557,502 shares outstanding.
              What happened to GT Biopharma’s price movement after its last earnings report?
              GT Biopharma reported an EPS of -$0.548 in its last earnings report, beating expectations of -$0.55. Following the earnings report the stock price went down -1.695%.
                Which hedge fund is a major shareholder of GT Biopharma?
                Currently, no hedge funds are holding shares in GTBP

                Company Description

                GT Biopharma

                GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies based on its proprietary TriKE (Tri-specific Killer Engager) platform. Operating in the biotechnology and pharmaceuticals sector, the company is dedicated to the discovery and development of immuno-oncology products designed to harness and enhance the body's natural immune system to target and destroy cancer cells. GT Biopharma's core product candidates aim to address various hematologic malignancies and solid tumors, offering a novel approach to cancer treatment.

                GT Biopharma (GTBP) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Brainstorm Cell Therapeutics
                Aptorum Group
                Lyra Therapeutics

                Ownership Overview

                0.95%<0.01%98.67%
                Insiders
                <0.01% Other Institutional Investors
                98.67% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis